Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02008994 · ClinicalTrials.gov registry record · Phase 2

Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer

A Phase 2 study, sponsored by Sanford Health.

Terminated
Registry status
Phase 2
Development phase
5
Enrollment target

NCT02008994: Clinical Trial Phase 2 study, sponsored by Sanford Health.

NCT02008994 is a Phase 2 study that was terminated before completion, run by Sanford Health. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02008994, a Phase 2 study, was terminated before completion, sponsored by Sanford Health.

TERMINATED
Registry status
Phase 2
Development phase
5 participants
Enrollment target

Study Summary

Genes are the basic "instruction book" for the cells that make up our bodies and are made out of DNA. Many research studies are done to find the best possible way to treat patients with cancer. Recently there has been a great deal of interest in developing new anticancer agents that are more targeted to a patient's individual genetic information, as well as diseases caused by defects in a person's genes. Identification of precisely which treatments to use against a specific patient's tumor is challenging. In this study, four cutting-edge technologies will be used to identify genomic (information we get from DNA and RNA) and proteomic (information we get from proteins) targets for the treatment of your tumor. These four tests will be used together to gather information about your tumor giving doctors and scientists a better understanding of the structure of your tumor and what the best treatment or combination of treatments may be for you. The therapy you receive to treat your tumor will be based on your medical history, previous treatments for your disease if applicable, current state of health, and the findings from these four tests. The therapy you ultimately receive will be selected by your doctor in consultation with a panel of experts in cancer and cancer genomics (the Treatment Selection Committee).

Interventions

  • OTHER Genomic and Proteomic Profiling

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2013-09
Est. Completion 2014-01
Phase Phase 2
Sanford Health

34 total trials

Why NCT02008994 stopped before completion

NCT02008994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which Genomic and Proteomic Profiling is the first listed.

NCT02008994 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02008994 about?

NCT02008994 is a clinical study titled "Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer". Genes are the basic "instruction book" for the cells that make up our bodies and are made out of DNA. Many research studies are done to find the best possible way to treat patients with cancer. Recently there has been a great deal of interest in developing new anticancer agents that are more targete...

What is the current status of trial NCT02008994?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2013-09. Estimated completion is 2014-01.

What interventions are being tested in trial NCT02008994?

The interventions under investigation include: Genomic and Proteomic Profiling (OTHER).

Who is sponsoring clinical trial NCT02008994?

This trial is sponsored by Sanford Health, which has 34 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02008994's enrollment target sits among peer trials

5 2000th of 2000 the lowest of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02008994, the US trial registry maintained by the National Library of Medicine. NCT02008994 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.